{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:28:50Z","timestamp":1790270930168,"version":"4.1.0"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Ceftriaxone is widely used in pediatric outpatient care for its efficacy against respiratory and digestive system infections, yet its increasing association with severe immune hemolytic reactions requires heightened vigilance from pediatricians. This report details a rare and severe case of ceftriaxone-induced severe immune hemolytic anemia (IHA), hemolytic crisis, myocardial injury, liver injury, renal calculi, and cholecystolithiasis in a previously healthy 3-year-old child. The child, treated for bronchitis, experienced sudden pallor, limb stiffness, and altered consciousness following the fifth day of ceftriaxone infusion, with hemoglobin (Hb) levels precipitously dropping to 21\u00a0g\/L. Immediate cessation of ceftriaxone and the administration of oxygen therapy, blood transfusion, intravenous immunoglobulin (IVIG), and corticosteroids led to a gradual recovery. Despite initial improvements, the patient\u2019s condition necessitated extensive hospital care due to complications including myocardial injury, liver injury, renal calculi, and cholecystolithiasis. After a 12-day hospital stay and a 3-month follow-up, the child showed complete normalization of Hb and liver function and resolution of calculi. In children, ceftriaxone infusion may trigger severe, potentially fatal, hemolytic reactions. Pediatricians must promptly recognize symptoms such as pallor, limb stiffness, and unresponsiveness, indicative of ceftriaxone-induced severe IHA, and immediately discontinue the drug. Effective management includes timely blood transfusion, respiratory support, IVIG administration, and corticosteroids when necessary, along with rigorous vital signs monitoring. Continued vigilance is imperative, even after cessation of ceftriaxone, to promptly address any residual adverse effects.<\/jats:p>","DOI":"10.3389\/fphar.2024.1362668","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T04:58:26Z","timestamp":1710478706000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Ceftriaxone-induced severe hemolytic anemia, renal calculi, and cholecystolithiasis in a 3-year-old child: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Enfu","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huangjia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meili","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisha","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"B1","first-page":"826","article-title":"Ceftriaxone induced acute multi-organ failure syndrome in a Saudi boy with sickle cell disease","volume":"31","author":"Al-Hawsawi","year":"2010","journal-title":"Saudi Med. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1046\/j.1537-2995.1999.39111239.x","article-title":"Serology of antibodies to second- and third-generation cephalosporins associated with immune hemolytic anemia and\/or positive direct antiglobulin tests","volume":"39","author":"Arndt","year":"1999","journal-title":"Transfusion"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1080\/14656566.2023.2291075","article-title":"Novel pharmacotherapy for drug-induced immune hemolytic anemia","volume":"24","author":"Barcellini","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/01.PCC.0000161285.12396.FF","article-title":"Ceftriaxone-induced hemolytic anemia and hepatitis in an adolescent with hemoglobin SC disease","volume":"6","author":"Bell","year":"2005","journal-title":"Pediatr. Crit. Care Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMra2033982","article-title":"Autoimmune hemolytic anemias","volume":"385","author":"Berentsen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/s0022-3476(95)70417-5","article-title":"Fatal hemolysis induced by ceftriaxone in a child with sickle cell anemia","volume":"126","author":"Bernini","year":"1995","journal-title":"J. Pediatr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/jcu.20228","article-title":"Ceftriaxone-associated biliary pseudolithiasis in children","volume":"34","author":"Biner","year":"2006","journal-title":"J. Clin. Ultrasound"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.2169\/internalmedicine.46.0059","article-title":"Hypoxic hepatopathy: pathophysiology and prognosis","volume":"46","author":"Birrer","year":"2007","journal-title":"Intern Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0002-9343(88)90016-2","article-title":"Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency","volume":"84","author":"Bj\u00f6rkander","year":"1988","journal-title":"Am. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1289","DOI":"10.1542\/peds.2010-1570","article-title":"Ceftriaxone-induced hemolysis in a child with Lyme arthritis: a case for antimicrobial stewardship","volume":"128","author":"Boggs","year":"2011","journal-title":"Pediatrics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1056\/NEJMcp1900554","article-title":"Warm autoimmune hemolytic anemia","volume":"381","author":"Brodsky","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"736618","DOI":"10.3389\/fphar.2021.736618","article-title":"Status and safety signals of cephalosporins in children: a spontaneous reporting database study","volume":"12","author":"Cai","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B13","first-page":"315","article-title":"Sefalosporinlerle ili\u015fkili otoimm\u00fcn hemolitik anemi: bir vaka takdimi","volume":"49","author":"Candemir","year":"2006"},{"key":"B14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s11655-006-0268-1","article-title":"Effect of compound glycyrrhizin injection on liver function and cellular immunity of children with infectious mononucleosis complicated liver impairment","volume":"12","author":"Cao","year":"2006","journal-title":"Chin. J. Integr. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1051887","DOI":"10.3389\/fped.2022.1051887","article-title":"Ceftriaxone-induced cholestatic hepatitis in a child: a case report and a review of the literature","volume":"10","author":"Castellazzi","year":"2022","journal-title":"Front. Pediatr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1012638","DOI":"10.3389\/fpubh.2022.1012638","article-title":"Case report: severe acute hepatitis in a 22-month-old Chinese boy with Omicron sub-variant BA.2.38","volume":"10","author":"Chen","year":"2022","journal-title":"Front. Public Health"},{"key":"B17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.bbrc.2011.02.053","article-title":"Ceftriaxone crystallization and its potential role in kidney stone formation","volume":"406","author":"Chutipongtanate","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1440-1754.2002.00778.x","article-title":"Ceftriaxone-induced haemolytic anaemia in a child with no immune deficiency or haematological disease","volume":"38","author":"Citak","year":"2002","journal-title":"J. Paediatr. Child. Health"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.3390\/cells12192417","article-title":"Anti-inflammatory and immunomodulatory effect of high-dose immunoglobulins in children: from approved indications to off-label use","volume":"12","author":"Conti","year":"2023","journal-title":"Cells"},{"key":"B20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40265-017-0853-7","article-title":"Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment","volume":"78","author":"Daudon","year":"2018","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00467-006-0043-4","article-title":"Ceftriaxone-related hemolysis and acute renal failure","volume":"21","author":"Demirkaya","year":"2006","journal-title":"Pediatr. Nephrol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s004310051261","article-title":"Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis","volume":"158","author":"de Moor","year":"1999","journal-title":"Eur. J. Pediatr."},{"key":"B23","first-page":"13A","article-title":"Successful treatment of life-threatening ceftriaxone-induced hemolysis by plasmapheresis in a 4-year old girl","volume":"49","author":"Doratotaj","year":"2009","journal-title":"Transfusion"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical Practice guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J. Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1007\/s00431-023-05091-0","article-title":"Evaluation of ceftriaxone pharmacokinetics in hospitalized Egyptian pediatric patients","volume":"182","author":"Eldougdoug","year":"2023","journal-title":"Eur. J. Pediatr."},{"key":"B26","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/1744666X.2022.2089115","article-title":"Autoimmune hemolytic anemia: causes and consequences","volume":"18","author":"Fattizzo","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/s0168-8278(00)80412-2","article-title":"Liver regeneration","volume":"32","author":"Fausto","year":"2000","journal-title":"J. Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40264-023-01316-1","article-title":"Nephrotoxicity of amoxicillin and third-generation cephalosporins: an updated review","volume":"46","author":"Garnier","year":"2023","journal-title":"Drug Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1182\/asheducation-2009.1.73","article-title":"Drug-induced immune hemolytic anemia","volume":"2009","author":"Garratty","year":"2009","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.blre.2010.06.004","article-title":"Immune hemolytic anemia associated with drug therapy","volume":"24","author":"Garratty","year":"2010","journal-title":"Blood Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1517\/14740338.2012.678832","article-title":"Immune hemolytic anemia caused by drugs","volume":"11","author":"Garratty","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/tjg.2014.3907","article-title":"A retrospective review of children with gallstone: single-center experience from Central Anatolia","volume":"25","author":"G\u00f6k\u00e7e","year":"2014","journal-title":"Turk J. Gastroenterol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/PEC.0b013e3182131fa8","article-title":"Severe hemolytic crisis after ceftriaxone administration","volume":"27","author":"Goyal","year":"2011","journal-title":"Pediatr. Emerg. Care"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/j.1537-2995.2004.03378.x","article-title":"Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells","volume":"44","author":"Grossjohann","year":"2004","journal-title":"Transfusion"},{"key":"B35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/bjh.14654","article-title":"Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia","volume":"177","author":"Hill","year":"2017","journal-title":"Br. J. Haematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1136\/archdischild-2022-324143","article-title":"Outpatient parenteral antimicrobial therapy: how young is too young?","volume":"107","author":"Hodgson","year":"2022","journal-title":"Arch. Dis. Child."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1111\/trf.12138","article-title":"Prolonged ceftriaxone-induced immune thrombocytopenia due to impaired drug clearance: a case report","volume":"53","author":"Jacquot","year":"2013","journal-title":"Transfusion"},{"key":"B38","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1159\/000529110","article-title":"Adverse reactions associated with intravenous immunoglobulin administration in the treatment of neurological disorders: a systematic review","volume":"184","author":"Jiang","year":"2023","journal-title":"Int. Arch. Allergy Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4266\/acc.2019.00465","article-title":"Relationship between low hemoglobin levels and mortality in patients with septic shock","volume":"34","author":"Jung","year":"2019","journal-title":"Acute Crit. Care"},{"key":"B40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s12098-022-04469-6","article-title":"Autoimmune hemolytic anemia in children: clinical profile and outcome","volume":"91","author":"Kar","year":"2024","journal-title":"Indian J. Pediatr."},{"key":"B41","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3349\/ymj.2002.43.3.391","article-title":"Ceftriaxone induced immune hemolytic anemia: detection of drug-dependent antibody by ex-vivo antigen in urine","volume":"43","author":"Kim","year":"2002","journal-title":"Yonsei Med. J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/s0022-3476(95)70418-3","article-title":"Fatal hemolysis caused by ceftriaxone","volume":"126","author":"Lascari","year":"1995","journal-title":"J. Pediatr."},{"key":"B43","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40360-018-0257-7","article-title":"Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature","volume":"19","author":"Leicht","year":"2018","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.phrs.2019.04.025","article-title":"Natural products in licorice for the therapy of liver diseases: progress and future opportunities","volume":"144","author":"Li","year":"2019","journal-title":"Pharmacol. Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/jpm13040671","article-title":"Ceftriaxone administration associated with lithiasis in children: guilty or not? A systematic review","volume":"13","author":"Louta","year":"2023","journal-title":"J. Pers. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3923\/ijp.2018.896.900","article-title":"A fatal case report of ceftriaxone-induced hemolytic anemia and literature review in pediatrics","volume":"14","author":"Lu","year":"2018","journal-title":"Int. J. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1182\/bloodadvances.2023009801","article-title":"Drug-induced immune hemolytic anemia: detection of new signals and risk assessment in a nationwide cohort study","volume":"8","author":"Maquet","year":"2024","journal-title":"Blood Adv."},{"key":"B48","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/000992280404300207","article-title":"Life-threatenting ceftriaxone-induced immune hemolytic anemia in a child with Crohn's disease","volume":"43","author":"Mattis","year":"2004","journal-title":"Clin. Pediatr. (Phila)."},{"key":"B49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000440673","article-title":"Variability of findings in drug-induced immune haemolytic anaemia: experience over 20 Years in a single centre","volume":"42","author":"Mayer","year":"2015","journal-title":"Transfus. Med. Hemother"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1177\/147323001003800614","article-title":"Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in Chinese children","volume":"38","author":"Meng","year":"2010","journal-title":"J. Int. Med. Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1046\/j.1365-2141.1999.01434.x","article-title":"Fatal immune haemolysis due to a degradation product of ceftriaxone","volume":"105","author":"Meyer","year":"1999","journal-title":"Br. J. Haematol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1586\/ehm.11.60","article-title":"Classification and therapeutic approaches in autoimmune hemolytic anemia: an update","volume":"4","author":"Michel","year":"2011","journal-title":"Expert Rev. Hematol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s00467-006-0401-2","article-title":"Ceftriaxone associated nephrolithiasis: a prospective study in 284 children","volume":"22","author":"Mohkam","year":"2007","journal-title":"Pediatr. Nephrol."},{"key":"B54","first-page":"A8054","article-title":"Ceftriaxone-induced immune haemolytic anaemia and multi-organ failure","volume":"159","author":"Mulkens","year":"2015","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1060028014548310","article-title":"Ceftriaxone-induced immune hemolytic anemia","volume":"48","author":"Neuman","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1097\/MPH.0000000000000181","article-title":"Ceftriaxone-induced hemolytic anemia: case report and review of literature","volume":"37","author":"Northrop","year":"2015","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3343\/alm.2015.35.4.436","article-title":"Red blood cell transfusion in patients with autoantibodies: is it effective and safe without increasing hemolysis risk?","volume":"35","author":"Park","year":"2015","journal-title":"Ann. Lab. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/S0140-6736(00)04904-7","article-title":"An overview of the immune system","volume":"357","author":"Parkin","year":"2001"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/pbc.26101","article-title":"Unusual serological findings associated with ceftriaxone-induced immune hemolytic anemia in a child with disseminated low-grade glioma","volume":"63","author":"Pecker","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1111\/j.1651-2227.2011.02268.x","article-title":"Severe immune haemolytic anaemia due to ceftriaxone in a patient with congenital nephrotic syndrome","volume":"100","author":"Reis Boto","year":"2011","journal-title":"Acta Paediatr."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.32388\/Z08IKJ","article-title":"A case of Ceftriaxone-induced immune thrombocytopenia: a diagnostic and therapeutic dilemma","author":"Saha","year":"2023","journal-title":"Qeios"},{"key":"B62","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/s0022-3476(96)70456-0","article-title":"Hemolysis after treatment with ceftriaxone","volume":"128","author":"Scimeca","year":"1996","journal-title":"J. Pediatr."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s001340000598","article-title":"Ceftriaxone-induced immune haemolysis: two case reports and a concise review of the literature","volume":"26","author":"Seltsam","year":"2000","journal-title":"Intensive Care Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1097\/MEG.0000000000000726","article-title":"Gallstones in childhood: etiology, clinical features, and prognosis","volume":"28","author":"Serdaroglu","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1097\/00005392-200210010-00003","article-title":"Uric acid nephrolithiasis: current concepts and controversies","volume":"168","author":"Shekarriz","year":"2002","journal-title":"J. Urol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"10600280231189897","DOI":"10.1177\/10600280231189897","article-title":"A real-world disproportionality analysis of drug-induced immune hemolytic anemia in the FDA adverse event reporting system","author":"Tang","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"B67","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s10354-008-0592-1","article-title":"Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases","volume":"158","author":"Trauner","year":"2008","journal-title":"Wien Med. Wochenschr"},{"key":"B68","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/trf.14536","article-title":"Ceftriaxone-induced drug reaction mimicking acute splenic sequestration crisis in a child with hemoglobin SC disease","volume":"58","author":"Van Buren","year":"2018","journal-title":"Transfusion"},{"key":"B69","doi-asserted-by":"publisher","first-page":"216","DOI":"10.24953\/turkjped.2016.02.016","article-title":"Ceftriaxone-induced hemolytic anemia in a child successfully managed with intravenous immunoglobulin","volume":"58","author":"Vehapo\u011flu","year":"2016","journal-title":"Turk J. Pediatr."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.2174\/1389557516666160801092713[","article-title":"Research progress of mechanisms of ceftriaxone associated nephrolithiasis","volume":"17","author":"Wang","year":"2017","journal-title":"Mini Rev. Med. Chem."},{"key":"B71","first-page":"493","volume-title":"Hematologic diseases","author":"Wells","year":"1991"},{"key":"B72","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/archdischild-2019-317950","article-title":"Safety of ceftriaxone in paediatrics: a systematic review","volume":"105","author":"Zeng","year":"2020","journal-title":"Arch. Dis. Child."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1097\/HEP.0000000000000041","article-title":"Runt-related transcription factor-1 ameliorates bile acid-induced hepatic inflammation in cholestasis through JAK\/STAT3 signaling","volume":"77","author":"Zhang","year":"","journal-title":"Hepatology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1007\/s00431-023-05146-2","article-title":"Drug-associated kidney injury in children: a disproportionality analysis of the FDA Adverse Event Reporting System","volume":"182","author":"Zhang","year":"","journal-title":"Eur. J. Pediatr."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1362668\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T04:58:32Z","timestamp":1710478712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1362668\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":74,"alternative-id":["10.3389\/fphar.2024.1362668"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1362668","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"article-number":"1362668"}}